Table_1_Two Novel Bacteriophages Control Multidrug- and Methicillin-Resistant Staphylococcus pseudintermedius Biofilm.docx

As a primary bacterial pathogen in companion animals, Staphylococcus pseudintermedius has zoonotic potential. This pathogen exhibits multidrug resistance, including resistance to methicillin, and biofilm-forming ability, making it hard to eradicate with antimicrobial agents. One potential alternative is bacteriophage therapy. In this study, we first characterized the antimicrobial resistance profile of S. pseudintermedius from canine samples and isolated two novel bacteriophages, pSp-J and pSp-S, from canine pet parks in South Korea to potentially control S. pseudintermedius. The biological characteristics of phages were assessed, and the phages could infect most of the methicillin-resistant S. pseudintermedius strains. We found that these phages were stable under the typical environment of the body (~37°C, pH 7). We also assessed bacterial lysis kinetics using the two phages and their cocktail, and found that the phages could prevent biofilm formation at low doses and could degrade biofilm at high doses. Taken together, this study demonstrates that bacteriophages pSp-J and pSp-S isolated in this study can be used to potentially treat methicillin-resistant S. pseudintermedius.

作为伴侣动物的主要细菌性致病菌，中间葡萄球菌（Staphylococcus pseudintermedius）具备人畜共患病潜力。该致病菌不仅呈现多重耐药性（包括甲氧西林耐药性），还具备生物膜形成能力，这使得其难以通过抗菌剂实现根除。噬菌体疗法是一种潜在的替代治疗手段。本研究首先对犬源分离的中间葡萄球菌的抗菌耐药谱进行了表征，并从韩国犬只宠物公园中分离得到两株新型噬菌体pSp-J与pSp-S，以期用于防控中间葡萄球菌。随后我们评估了这两株噬菌体的生物学特性，结果显示二者可感染绝大多数耐甲氧西林中间葡萄球菌菌株。研究表明，这些噬菌体在机体典型环境（约37℃、pH 7）下可保持稳定。我们还利用这两株噬菌体及其混合制剂开展了细菌裂解动力学评估，发现低剂量噬菌体可抑制生物膜形成，高剂量噬菌体则可降解已形成的生物膜。综上，本研究证实本研究中分离得到的噬菌体pSp-J与pSp-S可潜在用于治疗耐甲氧西林中间葡萄球菌感染。